A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR FLUORIDE UPTAKE BY BONE

被引:24
|
作者
RAO, HV
BELILES, RP
WHITFORD, GM
TURNER, CH
机构
[1] US EPA,WASHINGTON,DC 20460
[2] MED COLL GEORGIA,DEPT ORAL BIOL,AUGUSTA,GA 30912
[3] INDIANA SCH MED,DEPT ORTHOPED SURG,INDIANAPOLIS,IN 46202
关键词
D O I
10.1006/rtph.1995.1065
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A sex-specific, physiologically based pharmacokinetic (pbpk) model has been developed to describe the absorption, distribution, and elimination of fluorides in rats and humans. Growth curves generated by plotting mean body weights (kg) against age (weeks or years) are included in the simulation model to allow the integration of chronic fluoride exposure from birth to old age. The model incorporates age and body weight dependence of the physiological processes that control the uptake of fluoride by bone and the elimination of fluoride by the kidneys. Six compartments make up the model. These are lung, liver, kidney, bone, and slowly and rapidly perfused compartments. The model also includes two bone subcompartments: a small, flow-limited, rapidly exchangeable surface bone compartment and a bulk virtually nonexchangeable inner bone compartment. The inner bone compartment contains nearly all of the whole body content of fluoride, which, in the longer time frame, may be mobilized through the process of bone modeling and remodeling. The model has been validated by comparing the model predictions with experimental data gathered in rats and humans after drinking water and dietary ingestion of fluoride. This physiological model description of absorption, distribution, and elimination of fluoride from the body permits the analysis of the combined effect of ingesting and inhaling fluorides on the target organ, bone. Estimates of fluoride concentrations in bone are calculated and related to chronic fluoride toxicity. The model is thus useful for predicting some of the long-term metabolic features and tissue concentrations of fluoride that may be of value in understanding positive or negative effects of fluoride on human health. In addition, the pbpk model provides a basis for across-species extrapolation of the effective fluoride dose at the target tissue, bone, in the assessment of risk from different exposure conditions. (C) 1995 Academic Press, Inc.
引用
收藏
页码:30 / 42
页数:13
相关论文
共 50 条
  • [31] Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data
    Hornik, Christoph P.
    Wu, Huali
    Edginton, Andrea N.
    Watt, Kevin
    Cohen-Wolkowiez, Michael
    Gonzalez, Daniel
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1343 - 1353
  • [32] Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction
    Lu, Jingtao
    Goldsmith, Michael-Rock
    Grulke, Christopher M.
    Chang, Daniel T.
    Brooks, Raina D.
    Leonard, Jeremy A.
    Phillips, Martin B.
    Hypes, Ethan D.
    Fair, Matthew J.
    Tornero-Velez, Rogelio
    Johnson, Jeffre
    Dary, Curtis C.
    Tan, Yu-Mei
    PLOS COMPUTATIONAL BIOLOGY, 2016, 12 (02)
  • [33] Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
    Yang, Raymond S. H.
    Chang, Louis W.
    Yang, Chung Shi
    Lin, Pinpin
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (12) : 8482 - 8490
  • [34] Have physiologically-based pharmacokinetic models delivered?
    Edginton, Andrea N.
    Joshi, Ghanashyam
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (08) : 929 - 934
  • [35] Applications of minimal physiologically-based pharmacokinetic models
    Yanguang Cao
    William J. Jusko
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 711 - 723
  • [36] Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin
    Bowman, Christine M.
    Ma, Fang
    Mao, Jialin
    Chen, Yuan
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (01): : 5 - 17
  • [37] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING AND BIOACTIVATION OF XENOBIOTICS
    CLEWELL, HJ
    ANDERSEN, ME
    TOXICOLOGY AND INDUSTRIAL HEALTH, 1994, 10 (1-2) : 1 - 24
  • [38] Physiologically-based pharmacokinetic modeling of pyrene in the rat
    Haddad, S
    Withey, J
    Laparé, S
    Law, F
    Krishnan, K
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 1998, 5 (04) : 245 - 255
  • [39] A Δ9-Tetrahydrocannabinol Physiologically-Based Pharmacokinetic Model Development in Humans
    Methaneethorn, Janthima
    Poomsaidorn, Chomkanang
    Naosang, Kanyamas
    Kaewworasut, Parichart
    Lohitnavy, Manupat
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (04) : 495 - 511
  • [40] Evaluating a physiologically-based pharmacokinetic model for use in risk assessment.
    Clark, LH
    Barton, HA
    Setzer, RW
    TOXICOLOGICAL SCIENCES, 2003, 72 : 182 - 182